Dihydromyricetin (DHM) for Stage IV Cancer
Also known as: DHM, Ampelopsin, Ampelopsis grossedentata extract
DHM inhibits multiple cancer signaling pathways and reduces chemotherapy-induced liver damage.
Mechanism of Action
DHM inhibits PI3K/Akt/mTOR, STAT3, and NF-κB signaling in cancer cells. It induces apoptosis, inhibits metastasis through MMP suppression, and protects the liver from chemotherapy-induced hepatotoxicity through Nrf2 activation.
General mechanism: Flavonoid. GABA-A positive modulator, AMPK/SIRT1 activator, NLRP3 inhibitor, PI3K/mTOR suppressor, hepatoprotective.
Current Evidence
Preclinical anti-cancer evidence across hepatocellular, breast, and lung cancer. Liver-protective effects well-documented and clinically relevant for chemo patients.
Clinical Status: Preclinical for cancer. Liver protection studied clinically.
Safety Profile
Very safe. Well-tolerated. No significant side effects. Used traditionally in Chinese medicine.
Key Research Questions
- Can DHM protect the liver during hepatotoxic chemotherapy?
- Does DHM sensitize tumors to standard treatments?